Cost-effectiveness of percutaneous coronary intervention versus bypass surgery from a Dutch perspective

@article{Osnabrugge2015CosteffectivenessOP,
  title={Cost-effectiveness of percutaneous coronary intervention versus bypass surgery from a Dutch perspective},
  author={Ruben L. J. Osnabrugge and Elizabeth A. Magnuson and Patrick Wjc Serruys and Carlos M Campos and Kaijun Wang and David van Klaveren and Vasim Farooq and Mouin S. Abdallah and Haiyan Li and Katherine A. Vilain and Ewout Willem Steyerberg and Marie-claude Morice and Keith D. Dawkins and Friedrich W. Mohr and Arie Pieter Kappetein and David Joel Cohen},
  journal={Heart},
  year={2015},
  volume={101},
  pages={1980 - 1988}
}
Aims Recent cost-effectiveness analyses of percutaneous coronary intervention (PCI) versus coronary artery bypass grafting (CABG) have been limited by a short time horizon or were restricted to the US healthcare perspective. We, therefore, used individual patient-level data from the SYNTAX trial to evaluate the cost-effectiveness of PCI versus CABG from a European (Dutch) perspective. Methods and results Between 2005 and 2007, 1800 patients with three-vessel or left main coronary artery disease… 

Cost-effectiveness of bilateral vs. single internal thoracic artery grafts at 10 years

TLDR
Bilateral internal thoracic arteries for coronary artery bypass grafting has significantly higher costs but similar quality-adjusted survival at 10 years compared to SITA grafting, and extrapolation suggests this could change over lifetime.

Minimally invasive direct coronary artery bypass graft surgery versus percutaneous coronary intervention of the LAD: costs and long-term outcome

TLDR
Whereas patients undergoing MIDCAB remained longer on ICU and in hospital, causing higher costs, this procedure was associated with a significantly lower incidence of repeat revascularization and significantly lower mortality compared to PCI on the LAD.

Revascularization for Left Main and Multivessel Coronary Artery Disease: Current Status and Future Prospects after the EXCEL and NOBLE Trials

TLDR
The heart team approach to guide decision making in patients who are not presenting with ST-segment elevation myocardial infarction is discussed, including special populations that are not represented in clinical trials.

Costs of clinical events in type 2 diabetes mellitus patients in the Netherlands: A systematic review

TLDR
The most expensive clinical events were related to renal failure, while TIA was the least expensive event, and there was substantial variation in reported cost estimates for T2DM-related events.

Cost-effectiveness of procalcitonin testing to guide antibiotic treatment duration in critically ill patients: results from a randomised controlled multicentre trial in the Netherlands

TLDR
Although the impact of PCT guidance on total healthcare-related costs during the initial hospitalisation episode is likely negligible, the lower in-hospital mortality may lead to a non-significant increase in costs over a one-year time horizon.

A correlation analysis of blood flow and CK-MB in coronary bypass grafting

TLDR
There was a positive correlation between the CK-MB level and the blood flow volume/pulsatile index (correlation coefficient = 0.424 or 0.523) with a significant difference (P<0.05), suggesting the maintenance of circulation stability during surgery is of critical importance for alleviating myocardial injuries and improving cardiac function after surgery.

Expecting the holistic regulation from Chinese medicine based on the “solar system” hypothesis of ischemic heart disease

TLDR
Chinese medicine has been used in the real-world setting to manage a variety of diseases, including IHD, for more than two thousands years and the evidence of CM that supports the “solar system” IHD hypothesis is summarized.

References

SHOWING 1-10 OF 31 REFERENCES

Economic outcomes of percutaneous coronary intervention with drug‐eluting stents versus bypass surgery for patients with left main or three‐vessel coronary artery disease: One‐year results from the SYNTAX trial

  • D. CohenT. Lavelle A. Kappetein
  • Medicine, Political Science
    Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions
  • 2012
TLDR
Among patients with three‐vessel or left main CAD, PCI is an economically attractive strategy over the first year for patients with low and moderate angiographic complexity, while CABG is favored among patients with high angiography complexity.

A randomized trial comparing coronary angioplasty with coronary bypass surgery. Emory Angioplasty versus Surgery Trial (EAST)

TLDR
It was found that CABG and PTCA did not differ significantly with respect to the occurrence of the composite primary end point, and the selection of one procedure over the other should be guided by patients' preferences regarding the quality of life and the possible need for subsequent procedures.

A Randomized Trial Comparing Coronary Angioplasty with Coronary Bypass Surgery

TLDR
A three-year prospective, randomized trial comparing the outcomes of percutaneous transluminal coronary angioplasty as compared with coronary-artery bypass grafting for patients with multivessel coronary artery disease.

Three-Year Outcome After Coronary Stenting Versus Bypass Surgery for the Treatment of Multivessel Disease

TLDR
Three-year survival rates without stroke and myocardial infarction are identical in both groups, and the cost/benefit ratio of stenting is determined primarily by the increasing need for revascularization in the PCI group.

Multivessel coronary artery disease: quantifying how recent trials should influence clinical practice

TLDR
Economic considerations will increasingly be included in decision-making, since the economic impact of ischemic heart disease is high and the growth of healthcare expenditure is unsustainable, and CABG is associated with higher upfront costs, but is economically attractive at long-term follow-up.

Comparison of coronary-artery bypass surgery and stenting for the treatment of multivessel disease.

TLDR
As measured one year after the procedure, coronary stenting for multivessel disease is less expensive than bypass surgery and offers the same degree of protection against death, stroke, and myocardial infarction, however, stenting is associated with a greater need for repeated revascularization.

Strategies for multivessel revascularization in patients with diabetes.

TLDR
For patients with diabetes and advanced coronary artery disease, CABG was superior to PCI in that it significantly reduced rates of death and myocardial infarction, with a higher rate of stroke.

Comparison of coronary bypass surgery with angioplasty in patients with multivessel disease.

TLDR
It is found that in selected patients with multivessel disease suitable for treatment with either procedure, an initial strategy of PTCA does not result in a poorer five-year clinical outcome than CABG, although subsequent revascularization was required more often with this strategy.